Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal
12 Junio 2023 - 3:15PM
Business Wire
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or
“Revelation”), a life sciences company that is focused on the
development of immunologic based therapies for the prevention and
treatment of disease, today announced that the Company has
adjourned its 2023 Annual Meeting of Stockholders (the “Annual
Meeting”) originally scheduled to be held on June 9, 2023, to July
7, 2023, at 1:00 p.m., Eastern Time, or at such other time or such
other date to which the meeting may be adjourned.
On June 9, 2023, the Company called to order its Annual Meeting.
At the Annual Meeting, there were not present in person or by proxy
at least a majority of the Company’s common stock outstanding as of
the record date of May 5, 2023 in order to constitute a quorum that
is required to transact business at the Annual Meeting. Therefore,
the Company adjourned the Annual Meeting until July 7, 2023, at
1:00 p.m. Eastern Time. At that time, the Annual Meeting will be
reconvened virtually. An additional proposal to ratify the
appointment of Baker Tilly US, LLP as our independent auditor for
the fiscal year ending December 31, 2023 has also been added to be
voted on by stockholders at the Annual Meeting.
Whether or not stockholders plan to attend the Annual Meeting,
the Company encourages all stockholders to vote and submit their
proxies in advance of the Annual Meeting by one of the methods
described in the previously distributed proxy materials for the
Annual Meeting. The record date of May 5, 2023, set to determine
which stockholders are entitled to attend or vote at the Annual
Meeting has not changed.
In order to vote on the newly-added proposal, the stockholders
must sign and return the revised proxy card or attend the virtual
Annual Meeting and vote in person. The Company requests that the
stockholder complete the revised proxy card with the vote on
Proposals 1, 2 and 3, regardless of whether or not the stockholder
has already returned the original proxy card previously sent. If
the stockholder has already completed and returned the original
proxy card, by completing, signing and mailing the revised proxy
card the original proxy card will be replaced in its entirety and
only the vote as indicated on the revised proxy card will be
counted. If the stockholder has already voted and does not submit
new voting instructions, the previously submitted proxy or voting
instructions will be voted at the Annual Meeting with respect to
all other proposals but will not be counted in determining the
outcome of the newly added proposal.
If you have questions about the proposals or if you need
additional copies of this proxy statement/prospectus or the
enclosed proxy card you should contact our proxy solicitor at:
Advantage Proxy PO Box 10904 Yakima, WA 98909 Toll Free Phone:
1-877-870-8565 Collect: 1-206-870-8565 Email:
ksmith@advantageproxy.com
About Revelation Biosciences Inc.
Revelation Biosciences, Inc. is a life sciences company focused
on the development of immunologic-based therapies for the
prevention and treatment of disease. Revelation has multiple
product candidates in development that are based on the
well-established biology of phosphorylated hexaacyl disaccharide
(PHAD) and its effect on the innate immune system. REVTx‑300 is
being developed as a potential therapy for the treatment of acute
and chronic organ disease including CKD, AKI and myocarditis.
REVTx‑100 is being developed as a prevention and treatment of
infection. REVTx‑200 is being developed as an intranasal
immunomodulator adjunct to be used in combination with an
intramuscular vaccination for more complete immunity. REVTx‑99b is
being developed as a treatment for food allergies.
For more information on Revelation, please visit
www.RevBiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These forward-looking statements are generally
identified by the words "anticipate", "believe", "expect",
"estimate", "plan", "outlook", and "project" and other similar
expressions. We caution investors that forward-looking statements
are based on management’s expectations and are only predictions or
statements of current expectations and involve known and unknown
risks, uncertainties and other factors that may cause actual
results to be materially different from those anticipated by the
forward-looking statements. Revelation cautions readers not to
place undue reliance on any such forward looking statements, which
speak only as of the date they were made. The following factors,
among others, could cause actual results to differ materially from
those described in these forward-looking statements: the ability of
Revelation to meet its financial and strategic goals, due to, among
other things, competition; the ability of Revelation to grow and
manage growth profitability and retain its key employees; the
possibility that the Revelation may be adversely affected by other
economic, business, and/or competitive factors; risks relating to
the successful development of Revelation’s product candidates; the
clinical utility of an increase in intranasal cytokine levels as a
biomarker of viral infections; the ability to successfully complete
planned clinical studies of its product candidates; the risk that
we may not fully enroll our clinical studies or enrollment will
take longer than expected; risks relating to the occurrence of
adverse safety events and/or unexpected concerns that may arise
from data or analysis from our clinical studies; changes in
applicable laws or regulations; expected initiation of the clinical
studies, the timing of clinical data; the outcome of the clinical
data, including whether the results of such study is positive or
whether it can be replicated; the outcome of data collected,
including whether the results of such data and/or correlation can
be replicated; the timing, costs, conduct and outcome of our other
clinical studies; the anticipated treatment of future clinical data
by the FDA, the EMA or other regulatory authorities, including
whether such data will be sufficient for approval; the success of
future development activities for its product candidates; potential
indications for which product candidates may be developed; the
potential impact that COVID-19 may have on Revelation’s suppliers,
vendors, regulatory agencies, employees and the global economy as a
whole; the ability of Revelation to maintain the listing of its
securities on NASDAQ; investor sentiment relating to SPAC related
going public transactions; the expected duration over which
Revelation’s balances will fund its operations; and other risks and
uncertainties described herein, as well as those risks and
uncertainties discussed from time to time in other reports and
other public filings with the SEC by Revelation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230612958482/en/
Sandra Vedrick Vice President, Investor Relations & Human
Resources Revelation Biosciences Inc. Email:
svedrick@revbiosciences.com
and
Chester Zygmont, III Chief Financial Officer Revelation
Biosciences Inc. Email: czygmont@revbiosciences.com
Revelation Biosciences (NASDAQ:REVB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Revelation Biosciences (NASDAQ:REVB)
Gráfica de Acción Histórica
De May 2023 a May 2024